FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207531893> ?p ?o ?g. }

• W3207531893 endingPage "180" @default.
• W3207531893 startingPage "169" @default.
• W3207531893 abstract "Resistance to trastuzumab in breast cancer is an ongoing challenge. Clinical and biological effects of co-targeting HER2 and mammalian target of rapamycin (mTOR) in patients with HER2-positive early operable breast cancer via the addition of everolimus to preoperative trastuzumab were evaluated in a phase II randomised study.Patients were randomised 1:1 to receive trastuzumab (4 mg/kg initial dose then 2 mg/kg weekly for 5 weeks) alone or combined with everolimus (10 mg/day for 6 weeks) and then underwent surgery. Tumours were assessed by clinical examination and echography at the baseline and on treatment. The primary end-point was the clinical response rate at 6 weeks. Pathological response and safety were also evaluated. Baseline and surgery tumour samples were assessed by immunohistochemistry and multiplex immunoanalysis for predictive downstream effectors of the PI3K/AKT/mTOR and MAP kinase (MAPK) pathways.Eighty-two patients were enrolled, 41 per arm. The clinical response rates were 34.1% and 43.9% with trastuzumab alone and combined with everolimus, respectively. Pathological response rates were 43.6% and 47.5%, respectively. Addition of everolimus increased toxicity, notably mucositis (82.5% versus 5.0%) and rash (57.5% versus 10.0%), but grade III/IV events were rare. No correlation between response to treatments and baseline candidate biomarkers was identified, except for PIK3CA mutations which were found to predict trastuzumab resistance. Significant changes were seen in several MAPK pathway effectors after combination therapy.The addition of everolimus did not improve the efficacy, but induced MAPK signalling. Combination therapy to overcome pathway cross-talk should be considered to maximise the effectiveness of trastuzumab in this setting. ClinicalTrial.gov Identifier NCT00674414." @default.
• W3207531893 created "2021-10-25" @default.
• W3207531893 creator A5004048701 @default.
• W3207531893 creator A5009030272 @default.
• W3207531893 creator A5015172846 @default.
• W3207531893 creator A5018363275 @default.
• W3207531893 creator A5022517601 @default.
• W3207531893 creator A5034788813 @default.
• W3207531893 creator A5039278929 @default.
• W3207531893 creator A5040712210 @default.
• W3207531893 creator A5041410352 @default.
• W3207531893 creator A5043993292 @default.
• W3207531893 creator A5056565799 @default.
• W3207531893 creator A5071553983 @default.
• W3207531893 creator A5072315367 @default.
• W3207531893 creator A5072355411 @default.
• W3207531893 creator A5074932302 @default.
• W3207531893 creator A5075141136 @default.
• W3207531893 creator A5076243488 @default.
• W3207531893 creator A5079971350 @default.
• W3207531893 creator A5086379442 @default.
• W3207531893 date "2021-11-01" @default.
• W3207531893 modified "2023-10-14" @default.
• W3207531893 title "A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)" @default.
• W3207531893 cites W1861759122 @default.
• W3207531893 cites W2017999136 @default.
• W3207531893 cites W2055831769 @default.
• W3207531893 cites W2059411043 @default.
• W3207531893 cites W2082117763 @default.
• W3207531893 cites W2089605820 @default.
• W3207531893 cites W2103808574 @default.
• W3207531893 cites W2104337757 @default.
• W3207531893 cites W2105196235 @default.
• W3207531893 cites W2107426197 @default.
• W3207531893 cites W2107758515 @default.
• W3207531893 cites W2112434826 @default.
• W3207531893 cites W2113458582 @default.
• W3207531893 cites W2129803003 @default.
• W3207531893 cites W2138222867 @default.
• W3207531893 cites W2146384083 @default.
• W3207531893 cites W2149908785 @default.
• W3207531893 cites W2151082560 @default.
• W3207531893 cites W2162794726 @default.
• W3207531893 cites W2164429641 @default.
• W3207531893 cites W2218304281 @default.
• W3207531893 cites W2259054892 @default.
• W3207531893 cites W2318605753 @default.
• W3207531893 cites W2341308894 @default.
• W3207531893 cites W2517105328 @default.
• W3207531893 cites W2727007548 @default.
• W3207531893 cites W2743639018 @default.
• W3207531893 cites W2775764871 @default.
• W3207531893 cites W2799435517 @default.
• W3207531893 cites W2943699531 @default.
• W3207531893 cites W2945564879 @default.
• W3207531893 cites W2996625978 @default.
• W3207531893 cites W3004458066 @default.
• W3207531893 cites W3014181425 @default.
• W3207531893 cites W3080313180 @default.
• W3207531893 cites W3109453522 @default.
• W3207531893 doi "https://doi.org/10.1016/j.ejca.2021.09.017" @default.
• W3207531893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34678678" @default.
• W3207531893 hasPublicationYear "2021" @default.
• W3207531893 type Work @default.
• W3207531893 sameAs 3207531893 @default.
• W3207531893 citedByCount "9" @default.
• W3207531893 countsByYear W32075318932022 @default.
• W3207531893 countsByYear W32075318932023 @default.
• W3207531893 crossrefType "journal-article" @default.
• W3207531893 hasAuthorship W3207531893A5004048701 @default.
• W3207531893 hasAuthorship W3207531893A5009030272 @default.
• W3207531893 hasAuthorship W3207531893A5015172846 @default.
• W3207531893 hasAuthorship W3207531893A5018363275 @default.
• W3207531893 hasAuthorship W3207531893A5022517601 @default.
• W3207531893 hasAuthorship W3207531893A5034788813 @default.
• W3207531893 hasAuthorship W3207531893A5039278929 @default.
• W3207531893 hasAuthorship W3207531893A5040712210 @default.
• W3207531893 hasAuthorship W3207531893A5041410352 @default.
• W3207531893 hasAuthorship W3207531893A5043993292 @default.
• W3207531893 hasAuthorship W3207531893A5056565799 @default.
• W3207531893 hasAuthorship W3207531893A5071553983 @default.
• W3207531893 hasAuthorship W3207531893A5072315367 @default.
• W3207531893 hasAuthorship W3207531893A5072355411 @default.
• W3207531893 hasAuthorship W3207531893A5074932302 @default.
• W3207531893 hasAuthorship W3207531893A5075141136 @default.
• W3207531893 hasAuthorship W3207531893A5076243488 @default.
• W3207531893 hasAuthorship W3207531893A5079971350 @default.
• W3207531893 hasAuthorship W3207531893A5086379442 @default.
• W3207531893 hasBestOaLocation W32075318931 @default.
• W3207531893 hasConcept C121608353 @default.
• W3207531893 hasConcept C126322002 @default.
• W3207531893 hasConcept C143998085 @default.
• W3207531893 hasConcept C185592680 @default.
• W3207531893 hasConcept C203092338 @default.
• W3207531893 hasConcept C2779699572 @default.
• W3207531893 hasConcept C2779786085 @default.
• W3207531893 hasConcept C530470458 @default.
• W3207531893 hasConcept C535046627 @default.

• next